Gabriella Kékesi

Dr. Gabriella Kékesi

orcid

Research Focus & Metrics

Academic Career Length

12Years (2015-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
9 May 2023 in Neuron
Verified
Journal Article
Open access
QLQun Li
Qun Li
YTYuichi Takeuchi
Yuichi Takeuchi
JWJiale Wang
Jiale Wang
LGLevente Gellért
Levente Gellért
LBLivia Barcsai
Livia Barcsai
ABAntal Berényi
Antal Berényi
Although the etiology of major depressive disorder remains poorly understood, reduced gamma oscillations is an emerging biomarker. Olfactory bulbectomy, an established model of depression that reduces limbic gamma oscillations, suffers from non-specific effects of structural damage. Here, we show that transient functional suppression of olfactory bulb neurons or their piriform cortex efferents decreased gamma oscillation power in limbic areas and induced depression-like behaviors in rodents. Enhancing transmission of gamma oscillations from olfactory bulb to limbic structures by closed-loop electrical neuromodulation alleviated these behaviors. By contrast, silencing gamma transmission by anti-phase closed-loop stimulation strengthened depression-like behaviors in naive animals. These induced behaviors were neutralized by ketamine treatment that restored limbic gamma power. Taken together, our results reveal a causal link between limbic gamma oscillations and depression-like behaviors in rodents. Interfering with these endogenous rhythms can affect behaviors in rodent models of depression, suggesting that restoring gamma oscillations may alleviate depressive symptoms.

1 May 2015 in Behavioural Brain Research
Verified
Journal Article
Closed access
GKGabriella Kékesi
Gabriella Kékesi
ZPZ. Petrovszki
Z. Petrovszki
GBGyörgy Benedek
György Benedek
HGHorváth Gyöngyi
Horváth Gyöngyi

15 October 2019 in Molecules
Verified
Journal Article
Open access
PDF file
FZFerenc Zádor
Ferenc Zádor
Gábor Nagy-GróczGábor Nagy-Grócz
Gábor Nagy-Grócz
GKGabriella Kékesi
Gabriella Kékesi
SDSzabolcs Dvorácskó
Szabolcs Dvorácskó
ESEdina Szűcs
Edina Szűcs
László VécseiLászló Vécsei
László Vécsei
Schizophrenia, which affects around 1% of the world’s population, has been described as a complex set of symptoms triggered by multiple factors. However, the exact background mechanisms remain to be explored, whereas therapeutic agents with excellent effectivity and safety profiles have yet to be developed. Kynurenines and the endocannabinoid system (ECS) play significant roles in both the development and manifestation of schizophrenia, which have been extensively studied and reviewed previously. Accordingly, kynurenines and the ECS share multiple features and mechanisms in schizophrenia, which have yet to be reviewed. Thus, the present study focuses on the main common points and potential interactions between kynurenines and the ECS in schizophrenia, which include (i) the regulation of glutamatergic/dopaminergic/γ-aminobutyric acidergic neurotransmission, (ii) their presence in astrocytes, and (iii) their role in inflammatory mechanisms. Additionally, promising pharmaceutical approaches involving the kynurenine pathway and the ECS will be reviewed herein.

1 March 2015 in Brain Research Bulletin
Verified
Journal Article
Closed access
GTGabor Tuboly
Gabor Tuboly
LTLilla Tar
Lilla Tar
ZBZsuzsanna Bohar
Zsuzsanna Bohar
ASArpad Safrany-Fark
Arpad Safrany-Fark
ZPZita Petrovszki
Zita Petrovszki
HGHorváth Gyöngyi
Horváth Gyöngyi


1 January 2020 in Neuroscience Letters
Verified
Journal Article
Closed access
LBLászló Banki
László Banki
ABAlexandra Büki
Alexandra Büki
HGHorváth Gyöngyi
Horváth Gyöngyi
GKGabriella Kékesi
Gabriella Kékesi
GKGyongyi Kis
Gyongyi Kis
GTGabor Tuboly
Gabor Tuboly